Company Overview
IRADIMED CORPORATION functions within the healthcare sector, specifically operating in the medical devices industry, where it develops, manufactures, markets, and distributes specialized equipment designed for use within magnetic resonance imaging environments. The company's core product portfolio includes MRI compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems, along with related accessories that facilitate safe patient care during imaging procedures. This entity operates at a significant scale, evidenced by a current market capitalization of $1.24 billion and an annual revenue of $83.81 million generated by its operations. The company employs a workforce of 166 individuals, a headcount that reflects its established position as a specialized manufacturer rather than a mass-market conglomerate. The valuation metrics indicate that the market assigns a premium to the company's intellectual property and proprietary technology, as the market capitalization is nearly fifteen times the reported annual revenue, suggesting high expectations for future revenue generation from its niche product lines.
Financial Health
The company reported a trailing twelve-month revenue of $83.81 million, resulting in a net income of $22.48 million and an EBITDA of $27.31 million. The substantial gap between the revenue figure and the net income reveals a highly efficient cost structure, where operating expenses and taxes consume only approximately 26.8% of total revenue, leaving a robust profit margin. The business generated $6.64 million in free cash flow, which provides the organization with significant financial flexibility to fund research and development, acquire complementary technologies, or strengthen its balance sheet without relying on external capital markets. Profitability is further underscored by a gross margin of 76.7%, an operating margin of 31.3%, and a profit margin of 26.8%, indicating that the company retains a large portion of sales revenue after covering the direct costs of production and all operational overheads. Although specific debt figures are not disclosed in the provided data, the company holds $51.16 million in cash, creating a liquidity buffer that far exceeds any reported liability obligations. This strong liquidity position is confirmed by a current ratio of 7.98, which indicates that the company possesses nearly eight times the current assets necessary to cover its short-term liabilities, signaling an extremely low risk of liquidity distress. Furthermore, the company demonstrates exceptional capital efficiency with a return on equity of 24.8% and a return on assets of 15.8%, metrics that reveal management's ability to generate substantial returns on the capital invested by shareholders and in the company's asset base.
Valuation Assessment
Valuation multiples for IRADIMED CORPORATION reflect a high-cost equity profile, with a trailing twelve-month P/E ratio of 55.63 and a forward P/E of 41.97. The notable difference between the trailing and forward P/E ratios implies that the market expects earnings to grow significantly in the coming years, as the forward multiple is substantially lower than the trailing multiple despite the high absolute values. The price-to-book ratio stands at 13.15, indicating that the market values the company's equity at more than thirteen times its accounting book value, a premium typically associated with firms possessing valuable intangible assets or dominant market positions. Alternative valuation metrics further highlight the high valuation, with a price-to-sales ratio of 14.85 and an EV/EBITDA of 43.69, suggesting that investors are willing to pay a steep multiple for each dollar of sales and earnings due to the company's specialized nature. Regarding price action, the stock has traded between a 52-week low of $47.48 and a 52-week high of $107.90, meaning the current price sits at a level that reflects recent volatility but remains within the established annual trading range. The beta of 1.10 suggests that the stock price tends to be 10% more volatile than the broader market, meaning that during periods of general market rise or fall, IRADIMED's share price is expected to move with slightly greater magnitude than the index average.
Growth & Income
Growth metrics demonstrate a strong upward trajectory, with revenue growth of 17.0% year-over-year and earnings growth of 24.8% year-over-year. The fact that earnings are growing faster than revenue, as indicated by the higher percentage for earnings growth, implies that the company is improving its operational efficiency or expanding into higher-margin segments, thereby increasing profitability at a rate that outpaces top-line expansion. As a dividend payer, the company offers a dividend yield of 0.8% and maintains a payout ratio of 38.9%, a level that is highly sustainable given the strong earnings growth and substantial free cash flow generation. The payout ratio suggests that the company retains the majority of its earnings to reinvest in business growth while still providing a modest return to shareholders, a strategy often favored by growth-oriented investors who prefer capital appreciation over high current income. The overall growth and income profile combines a history of double-digit revenue expansion with a disciplined approach to dividend distribution, positioning the company as a hybrid investment that seeks to reward shareholders with both capital growth and a consistent, albeit modest, dividend stream.